Jenny Vu Pozadzides, Barbara Pro. Show Affiliations »
Abstract
Entities: Disease Gene
Mesh: See more » AdalimumabAntibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal, HumanizedAntineoplastic Agents/administration & dosageAntineoplastic Agents/adverse effectsHumansImmunosuppression/adverse effectsInfliximabLiver Neoplasms/mortalityLiver Neoplasms/physiopathologyLiver Neoplasms/therapyLymphoma, T-Cell/mortalityLymphoma, T-Cell/physiopathologyLymphoma, T-Cell/therapyMaleSplenic Neoplasms/mortalitySplenic Neoplasms/physiopathologySplenic Neoplasms/therapyTumor Necrosis Factor-alpha/antagonists & inhibitorsYoung Adult
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsTumor Necrosis Factor-alphaInfliximabAdalimumab
Year: 2009 PMID: 21082951 DOI: 10.1586/ehm.09.62
Source DB: PubMed Journal: Expert Rev Hematol ISSN: 1747-4094 Impact factor: 2.929